GlassScriptPhysician profile
Amit Ladani
NPI 1518278530
$7,616.67
in general payments reported to CMS, 2019-2025
37 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $979 · 2020: $754 · 2021: $1,175 · 2022: $1,053 · 2023: $1,264 · 2024: $1,313 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,655.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,247.58 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,092.08 | 2019-2024 | Xarelto |
| Amgen INC. | $757.43 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $747.87 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $441.42 | 2020-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $434.33 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $343.39 | 2019-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $279.63 | 2022-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $278.60 | 2019-2025 | |
| Scpharmaceuticals INC. | $258.64 | 2023-2025 | |
| Boston Scientific Corporation | $180.93 | 2021-2025 | Watchman Flx |
| Heartflow, INC. | $159.51 | 2022-2025 | |
| Esperion Therapeutics, INC. | $137.52 | 2020-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $119.43 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $118.04 | 2019-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Ladani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.